Related Experiment Video
Updated: Jan 13, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Do SGLT2is Improve End-of-Life Care in Adults with Advanced Heart Failure?
Media Mokhtarnia1,2, Kieran L Quinn1
1Temmy Latner Centre for Palliative Care and Division of Internal Medicine and Geriatrics, Department of Medicine, Sinai Health System, University of Toronto, Toronto, ON.
Abstract:
AbstractSodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) improve quality of life, functional capacity, and survival, and reduce hospitalization in adults with heart failure (HF). However, most controlled trials to date have enrolled few adults with advanced HF and multiple chronic illnesses. Despite favorable evidence in adults with HF, the safety and effectiveness of SGLT2 inhibitors on patient-centered outcomes in adults with advanced HF and multiple chronic illnesses remain unknown. This Tomorrow's Trial reviews the existing evidence and proposes a trial to address the question, "Do SGLT2 inhibitors improve end-of-life care in adults with advanced heart failure?"
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Heart Failure VII: Nursing Interventions